Atlas Trials

PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing

Clinical trial NCT04787302 · COMPLETED

Trial details

NCT number
NCT04787302
Sponsor
Cerevel Therapeutics, LLC
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Schizophrenia
Start date
2021-06-01
Primary completion
2023-07-14
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.